Lonnel Coats bought $95k of LXRX
Chief Executive Officer at LEXICON PHARMACEUTICALS, INC.. 90,000 shares at an average of $1.05, traded Nov 16, 2023, filed Nov 17, 2023.
Score components
- +25RoleCEO
- +10Trade size$95k at market
- +3Relative to holdingsHoldings up 11%
- +18Price context6% above the 52-week low; 70% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- +5Repeat buying2 buys in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +13.4%, 3m +183.9%, 6m +58.0%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001127602-23-027850, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 16, 2023 | POpen-market purchase Common Stock | +90,000 | $1.05 | $95k | 914,359 | Nov 17, 2023 |
Related signals
Other insiders at LEXICON PHARMACEUTICALS, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 15Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $2,980 2,000 shares | +0% | |
| 34Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $147k 100,000 shares | +6% | |
| 35Weak | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $220k 150,000 shares | +9% | |
| 41Moderate | LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $353k 268,497 shares | +19% | |
| 56Moderate | LEXICON PHARMACEUTICALS, INC. | Invus Global Management, LLC director, owner | $2.0M 1,538,462 shares | - | |
| 63Notable | LEXICON PHARMACEUTICALS, INC. | Philippe Amouyal director | $202k 200,000 shares | +496% | |
| 51Moderate | LEXICON PHARMACEUTICALS, INC. | Lonnel Coats Chief Executive Officer | $10k 10,000 shares | +1% | |
| 58Moderate | LXRXbuy LEXICON PHARMACEUTICALS, INC. | Raymond Debbane director | $1.1M 1,000,000 shares | +293% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.